Cargando…

Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition

BACKGROUND: Aboriginal and Torres Strait Islander people are disproportionately affected by hepatitis B virus (HBV) infection. A proposed mismatch between standard vaccines and the HBV/C4 sub‐genotype prevalent in Aboriginal people in the Northern Territory (NT) may reduce vaccine effectiveness. AIM...

Descripción completa

Detalles Bibliográficos
Autores principales: Qama, Ashleigh, Allard, Nicole, Cowie, Benjamin, Davis, Joshua S., Davies, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362129/
https://www.ncbi.nlm.nih.gov/pubmed/32975893
http://dx.doi.org/10.1111/imj.15069
_version_ 1783738095686909952
author Qama, Ashleigh
Allard, Nicole
Cowie, Benjamin
Davis, Joshua S.
Davies, Jane
author_facet Qama, Ashleigh
Allard, Nicole
Cowie, Benjamin
Davis, Joshua S.
Davies, Jane
author_sort Qama, Ashleigh
collection PubMed
description BACKGROUND: Aboriginal and Torres Strait Islander people are disproportionately affected by hepatitis B virus (HBV) infection. A proposed mismatch between standard vaccines and the HBV/C4 sub‐genotype prevalent in Aboriginal people in the Northern Territory (NT) may reduce vaccine effectiveness. AIMS: To determine HBV prevalence in the NT by Indigenous status and to explore patterns of immunity following implementation of universal vaccination, using a large longitudinal diagnostic dataset. METHODS: A retrospective analysis of all available HBV serology results in the NT from 1991 to 2011 was conducted, with HBV prevalence and vaccination status analysed according to adigenous status, age and sex using individuals' patterns of HBsAg, anti‐HBs and anti‐HBc serology over repeated tests. RESULTS: 100 790 individuals were tested (33.4% Indigenous) between 1991 and 2011 (26.1% of the 2011 NT population), with a total of 211 802 tests performed. In 2011, the proportion of HBV positive individuals in the NT was 3.17% (5.22% in Indigenous populations) compared to previous 2011 estimates of 1.70% (3.70% in Indigenous populations). The vaccine failure rate was lower than expected with only one presumed vaccinated person subsequently developing HBsAg positivity (0.02%). Evidence of suboptimal vaccine efficacy by breakthrough anti‐HBc positivity in vaccinated individuals was demonstrated in 3.1% of the vaccinated cohort, of which 86.4% identified as Indigenous (HR 1.17). No difference in HBeAg positivity or seroconversion was observed between Indigenous and non‐Indigenous individuals living with CHB. CONCLUSIONS: The burden of CHB in Indigenous people in the NT has previously been underestimated. A higher HBV prevalence in the NT than described in previous cross‐sectional studies was found, including a higher prevalence in Indigenous people. Evidence of suboptimal vaccine efficacy was demonstrated predominantly in Indigenous individuals.
format Online
Article
Text
id pubmed-8362129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-83621292021-08-17 Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition Qama, Ashleigh Allard, Nicole Cowie, Benjamin Davis, Joshua S. Davies, Jane Intern Med J Original Articles BACKGROUND: Aboriginal and Torres Strait Islander people are disproportionately affected by hepatitis B virus (HBV) infection. A proposed mismatch between standard vaccines and the HBV/C4 sub‐genotype prevalent in Aboriginal people in the Northern Territory (NT) may reduce vaccine effectiveness. AIMS: To determine HBV prevalence in the NT by Indigenous status and to explore patterns of immunity following implementation of universal vaccination, using a large longitudinal diagnostic dataset. METHODS: A retrospective analysis of all available HBV serology results in the NT from 1991 to 2011 was conducted, with HBV prevalence and vaccination status analysed according to adigenous status, age and sex using individuals' patterns of HBsAg, anti‐HBs and anti‐HBc serology over repeated tests. RESULTS: 100 790 individuals were tested (33.4% Indigenous) between 1991 and 2011 (26.1% of the 2011 NT population), with a total of 211 802 tests performed. In 2011, the proportion of HBV positive individuals in the NT was 3.17% (5.22% in Indigenous populations) compared to previous 2011 estimates of 1.70% (3.70% in Indigenous populations). The vaccine failure rate was lower than expected with only one presumed vaccinated person subsequently developing HBsAg positivity (0.02%). Evidence of suboptimal vaccine efficacy by breakthrough anti‐HBc positivity in vaccinated individuals was demonstrated in 3.1% of the vaccinated cohort, of which 86.4% identified as Indigenous (HR 1.17). No difference in HBeAg positivity or seroconversion was observed between Indigenous and non‐Indigenous individuals living with CHB. CONCLUSIONS: The burden of CHB in Indigenous people in the NT has previously been underestimated. A higher HBV prevalence in the NT than described in previous cross‐sectional studies was found, including a higher prevalence in Indigenous people. Evidence of suboptimal vaccine efficacy was demonstrated predominantly in Indigenous individuals. John Wiley & Sons Australia, Ltd 2021-06-21 2021-06 /pmc/articles/PMC8362129/ /pubmed/32975893 http://dx.doi.org/10.1111/imj.15069 Text en © 2020 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Qama, Ashleigh
Allard, Nicole
Cowie, Benjamin
Davis, Joshua S.
Davies, Jane
Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title_full Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title_fullStr Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title_full_unstemmed Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title_short Hepatitis B in the Northern Territory: insights into the changing epidemiology of an ancient condition
title_sort hepatitis b in the northern territory: insights into the changing epidemiology of an ancient condition
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362129/
https://www.ncbi.nlm.nih.gov/pubmed/32975893
http://dx.doi.org/10.1111/imj.15069
work_keys_str_mv AT qamaashleigh hepatitisbinthenorthernterritoryinsightsintothechangingepidemiologyofanancientcondition
AT allardnicole hepatitisbinthenorthernterritoryinsightsintothechangingepidemiologyofanancientcondition
AT cowiebenjamin hepatitisbinthenorthernterritoryinsightsintothechangingepidemiologyofanancientcondition
AT davisjoshuas hepatitisbinthenorthernterritoryinsightsintothechangingepidemiologyofanancientcondition
AT daviesjane hepatitisbinthenorthernterritoryinsightsintothechangingepidemiologyofanancientcondition